Search Results - Schuko, Nicolette

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants

    Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants by Roe, Tiffany L, Brady, Tyler, Schuko, Nicolette, Nguyen, Amy, Beloor, Jagadish, Guest, Johnathan D, Aksyuk, Anastasia A, Tuffy, Kevin M, Zhang, Tianhui, Streicher, Katie, Kelly, Elizabeth J, Kijak, Gustavo H

    Published in Microbiology spectrum
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

    Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial) by Kijak, Gustavo H., Ahani, Bahar, Arbetter, Douglas, Chuecos, Fernando, Gopalakrishnan, Vancheswaran, Beloor, Jagadish, Brady, Tyler, Nguyen, Amy, Roe, Tiffany L., Schuko, Nicolette, Zhang, Tianhui, Hobbs, F. D. Richard, Padilla, Francisco, Kelly, Elizabeth J., Montgomery, Hugh, Streicher, Katie

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

    Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants by Tuffy, Kevin M, Ahani, Bahar, Aksyuk, Anastasia A, Avila, Miles, Brady, Tyler, Kijak, Gustavo H, Koh, Gavin, Levin, Myron J, Roe, Tiffany L, Schuko, Nicolette, Thissen, Jesse, Ustianowski, Andrew, Zhang, Tianhui, Kelly, Elizabeth J, Streicher, Katie

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models

    Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SA... by Cong, Yu, Lee, Ji Hyun, Perry, Donna L., Cooper, Kurt, Wang, Hui, Dixit, Saurabh, Liu, David X., Feuerstein, Irwin M., Solomon, Jeffrey, Bartos, Christopher, Seidel, Jurgen, Hammoud, Dima A., Adams, Ricky, Anthony, Scott M., Liang, Janie, Schuko, Nicolette, Li, Rong, Liu, Yanan, Wang, Zhongde, Tarbet, E. Bart, Hischak, Amanda M.W., Hart, Randy, Isic, Nejra, Burdette, Tracey, Drawbaugh, David, Huzella, Louis M., Byrum, Russell, Ragland, Danny, St Claire, Marisa C., Wada, Jiro, Kurtz, Jonathan R., Hensley, Lisa E., Schmaljohn, Connie S., Holbrook, Michael R., Johnson, Reed F.

    Published in Antiviral research
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  5. 5
    1110. AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies

    1110. AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies by Tuffy, Kevin M, Abram, Michael E, Roe, Tiffany L, Ahani, Bahar, Brady, Tyler, Schuko, Nicolette, Clarke, Lori, Caceres, Carolina, Kenny, Tara, Takahashi, Virginia, Zhang, Tianhui, Tabor, David E, Kijak, Gustavo H, Kelly, Elizabeth J, Streicher, Katie

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    1160. Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults

    1160. Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVI... by Kijak, Gustavo H, Ahani, Bahar, Arbetter, Douglas, Brady, Tyler, Chuecos, Fernando, Gopalakrishnan, Vancheswaran, Roe, Tiffany L, Schuko, Nicolette, Richard Hobbs, F D, Padilla, Francisco, Kelly, Elizabeth J, Montgomery, Hugh, Streicher, Katie

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Longitudinal analyses using 18 F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models

    Longitudinal analyses using 18 F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 S... by Cong, Yu, Lee, Ji Hyun, Perry, Donna L, Cooper, Kurt, Wang, Hui, Dixit, Saurabh, Liu, David X, Feuerstein, Irwin M, Solomon, Jeffrey, Bartos, Christopher, Seidel, Jurgen, Hammoud, Dima A, Adams, Ricky, Anthony, Scott M, Liang, Janie, Schuko, Nicolette, Li, Rong, Liu, Yanan, Wang, Zhongde, Tarbet, E Bart, Hischak, Amanda M W, Hart, Randy, Isic, Nejra, Burdette, Tracey, Drawbaugh, David, Huzella, Louis M, Byrum, Russell, Ragland, Danny, St Claire, Marisa C, Wada, Jiro, Kurtz, Jonathan R, Hensley, Lisa E, Schmaljohn, Connie S, Holbrook, Michael R, Johnson, Reed F

    Published in Antiviral research
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: